The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

Launched by MATERIA MEDICA HOLDING · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Raphamin for adults with acute rhinosinusitis, which is an inflammation of the sinuses that can cause symptoms like facial pain, pressure, and nasal congestion. The trial aims to find out if Raphamin is effective and safe for helping patients feel better. To participate, individuals need to be between 18 and 75 years old and have experienced symptoms of acute rhinosinusitis for no longer than 48 hours. Participants must also have a certain level of symptoms, as measured by a scale, and should be willing to use contraception during the study.

Those who join the trial will be randomly assigned to receive either Raphamin or a placebo (a treatment that looks like the drug but has no active ingredients) without knowing which one they are getting. This helps researchers evaluate the true effects of Raphamin. Participants will be closely monitored for their health and any side effects throughout the study. It's important to note that people with certain health conditions or who have recently taken specific medications may not be eligible to participate. If you're considering joining, your doctor can help determine if you meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female aged 18 - 75 years.
• 2. Diagnosis of acute rhinosinusitis:
• • 8-12 points on MSS scale;
• • no more than 3 severe symptoms (3 points on the MSS scale)
• • facial pain/heaviness in the facial area 1-2 points on the MSS scale.
• • 3. Disease duration up to 48 hours (from the onset of the first symptoms of the disease).
• • 4. Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by the patient.
• • 5. Patients who agreed to use a reliable method of contraception during the study (for men and women of reproductive potential).
• Exclusion Criteria:
• 1. Symptoms of acute bacterial rhinosinusitis (three or more of those below):
• • fever of ≥ 38.0°C;
• • the second wave of ARS symptoms;
• • one-sided process;
• • facial pain/pressure of 3 points (on the MSS scale).
• • 2. Recurrent ARS (≥4 episodes of ARS per year with complete resolution of symptoms between episodes).
• • 3. Odontogenic rhinosinusitis.
• • 4. Allergic (seasonal or year-round) rhinitis.
• • 5. Nasal polyps or clinically significant nasal septum deviation.
• • 6. Concomitant otitis.
• • 7. Use of intranasal or systemic corticosteroids for 30 days prior to the screening visit.
• • 8. Use of intranasal or systemic antibiotics for 30 days prior to the screening visit.
• • 9. Surgery for the nasal cavity and paranasal sinuses during the last 6 months before the screening visit.
• • 10. Any other surgery during the last 3 months.
• • 11. Clinical symptoms of severe influenza/ARVI requiring hospitalization.
• • 12. Suspected bacterial infection of any localization requiring the administration of antibiotics from the first day of disease.
• • 13. History/suspicion of oncology of any localization (except for benign neoplasms).
• • 14. Exacerbation or decompensation of chronic diseases (diabetes mellitus, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ENT organs, etc.) affecting the patient's ability to participate in the clinical trial.
• • 15. Previously diagnosed immunodeficiency of any etiology.
• • 16. Unstable angina or myocardial infarction during the last 6 months.
• • 17. Class III and IV chronic heart failure (according to the classification of the New York Heart Association, 1964).
• • 18. History of chronic kidney disease (classes C3-5 A3).
• • 19. History of liver failure (class C according to Child-Pugh).
• • 20. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
• • 21. Pregnancy, breast-feeding, and childbirth less than 3 months before inclusion in the trial.
• • 22. Hypersensitivity to any component of the medicines used in the treatment.
• • 23. Patients who used medications listed under "Prohibited Concomitant Treatment" within 1 month prior to inclusion in the trial or need medications prohibited for use in the trial.
• • 24. Patients who, from the investigator's point of view, will not comply with the observation requirements during the trial or follow the procedure for taking the test drugs.
• • 25. History of mental illness, alcoholism, drug abuse, which, from the investigator's point of view, will prevent the patient from following the trial procedures.
• • 26. Participation in other clinical trials within 3 months prior to inclusion in this trial.
• • 27. Patient is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted.
• • 28. Patient is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.